# US 2017/0253916 A1 · Exosomal biomarkers diagnostic of tuberculosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253916 A1
- Document ID: US20170253916A1
- Status: Published application
- Kind: A1
- Application number: 15/449,324
- Filed: 2017-03-03
- Published: 2017-09-07
- Earliest claimed: 2016-03-04
- Assignees: University of Notre Dame du Lac
- Applicants: University of Notre Dame du Lac
- Inventors: Jeffrey S. SCHOREY; Prachi Pratap Singh; Yong Cheng
- Web page: https://patentgrep.com/patent/US20170253916A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosure provides a method for diagnosing an active mycobacterium tuberculosis infection by detecting certain RNA biomarkers present in secreted extracellular vesicles isolated from a bodily fluid. The RNA biomarkers in the secreted extracellular vesicles may include a certain mycobacterium RNAs as well as certain host cell RNAs. Also provided is an RNA signature of certain mycobacterium and host cell RNA present in secreted extracellular vesicles indicative of an active tuberculosis infection.

## Claims

### Claim 1

A method for identifying an active M. tuberculosis infection in a subject comprising:
isolating extracellular vesicles from bodily fluid of a subject, wherein the extracellular vesicles contain a plurality of RNA;
extracting at least a portion of the RNA from the extracellular vesicle; and
analyzing the RNA for the presence of one or more RNA that are indicative of an active M. tuberculosis infection, thereby determining the presence or absence of an active M. tuberculosis infection in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the RNA that are indicative of an active M. tuberculosis infection is selected from the group consisting of RV1821, RV1842c, RV3894c, RV0453, RV1629, RV0170, RV0668, RV0740, RV0288, RV1344, RV0968, RV1942c, RV0664, RV0190, RV1757c, RV1369c, RV3809c, RV3533, RV0243, RV1101c, and RV2024c.

### Claim 3 (depends on 1)

The method of claim 1, wherein the RNA that are indicative of an active M. tuberculosis infection is selected from the group consisting of 149-3p, 181c-5p, 1839-3p, 151-3p, 214-3p, 292-3p, 3107-5p, 3074-5p, 344i, 486-5p, 486-3p, 434-5p, 598-3p, 5099, 5113, 5106, 5097, 5621-5p, 5115, 5111-5p, 714, 877-3p, 759 and 713.

### Claim 4 (depends on 1)

The method of claim 1, further comprising providing a means for detecting the at least one RNA.

### Claim 5 (depends on 4)

The method of claim 4, wherein the means for detecting is a capture probe.

### Claim 6 (depends on 5)

The method of claim 5, wherein the capture probe comprises a nucleotide sequence at least partially complementary to RNA sought to be detected.

### Claim 7 (depends on 1)

The method of claim 1, wherein analyzing the RNA comprises creating cDNA from the plurality of RNA.

### Claim 8 (depends on 7)

The method of claim 7, further comprising quantitating a level of one or more of the extracted RNA using qRT-PCR.

### Claim 9 (depends on 1)

The method of claim 1, wherein the bodily fluid comprises blood, blood serum, blood plasma or urine.

### Claim 10 (depends on 1)

The method of claim 1, further comprising comparing an RNA expression profile of the RNA extracted from the subject with a second RNA expression profile from a control subject.

### Claim 11 (depends on 1)

The method of claim 1, wherein the extracellular vesicles are concentrated prior to extracting the RNA.

### Claim 12 (depends on 1)

The method of claim 1, wherein the extracellular vesicles are exosomes.

### Claim 13

An RNA signature diagnostic of an active M. tuberculosis infection, wherein the RNA signature comprises at least one RNA isolated from an extracellular vesicle secreted from an M. tuberculosis infected cell.

### Claim 14 (depends on 13)

The RNA signature of claim 13, wherein the RNA signature comprises at least one RNA selected from the group consisting of RV1821, RV1842c, RV3894c, RV0453, RV1629, RV0170, RV0668, RV0740, RV0288, RV1344, RV0968, RV1942c, RV0664, RV0190, RV1757c, RV1369c, RV3809c, RV3533, RV0243, RV1101c, and RV2024c.

### Claim 15 (depends on 13)

The RNA signature of claim 13, wherein the RNA signature comprises at least one RNA selected from the group consisting of 149-3p, 181c-5p, 1839-3p, 151-3p, 214-3p, 292-3p, 3107-5p, 3074-5p, 344i, 486-5p, 486-3p, 434-5p, 598-3p, 5099, 5113, 5106, 5097, 5621-5p, 5115, 5111-5p, 714, 877-3p, 759 and 713.

### Claim 16 (depends on 13)

The RNA signature of claim 13, wherein the extracellular vesicle is isolated from blood, blood serum, blood plasma or urine.

### Claim 17 (depends on 13)

The RNA signature of claim 13, wherein the RNA signature is detected using a capture probe comprising a nucleotide sequence at least partially complementary to the RNA of the RNA signature.

### Claim 18 (depends on 13)

The RNA signature of claim 13, wherein the extracellular vesicles are exosomes.
